Efficacy and safety of favipiravir and remdesivir in COVID-19 patients: Clinical data
https://doi.org/10.34215/1609-1175-2024-3-79-84
Abstract
Aim. To evaluate the efficacy and safety of favipiravir and remdesivir in the infectious disease hospital of the Volgograd region in 2022.
Materials and methods. In total, 559 medical records of patients prescribed favipiravir or remdesivir in 2022 were studied. Long-term results of the drug use and disease outcomes after discharge or transfer to another medical institution were assessed using the Federal registry of people with COVID-19.
Results. Favipiravir was more frequently prescribed in mild cases of the disease. After excluding patients without signs of lung injury from the analysis, there were no significant differences in mortality and improvement. Patients receiving favipiravir had lower odds of ALT elevations above 5 upper limits of normal and developing drug-induced liver injury with a possible RUCAM score compared with patients receiving remdesivir (OR = 0.40, 95CI 0.20–0.80 and OR = 0.30, 95 CI 0.08–1.08).
Conclusion. The limited experience of the use of favipiravir for COVID-19 necessitates further research into its efficacy and safety, particularly when prescribing warfarin and high doses of direct anticoagulants simultaneously.
About the Authors
V. I. Petrov
Volgograd State Medical University
Russian Federation
Russian Federation
Volgograd
A. Yu. Ryazanova
Volgograd State Medical University
Russian Federation
Russian Federation
Anastasia Yu. Ryazanova, Associate Professor of the Department of Clinical Pharmacology and Intensive Care
1, Pavshikh Bortsov Sq., Volgograd, 400131, Russia
phone: +7 (8442) 38-50-05
N. S. Tokareva
Volgograd State Medical University
Russian Federation
Russian Federation
Volgograd
References
1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–33. doi: 10.1016/j.bj.2020.04.007
2. Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med. 2020;288(1):128–38. doi: 10.1111/joim.13063
3. Sulaiman I, Chung M, Angel L, Tsay JJ, Wu BG, Yeung ST, Krolikowski K, Li Y, Duerr R, Schluger R, Thannickal SA, Koide A, Rafeq S, Barnett C, Postelnicu R, Wang C, Banakis S, Pérez-Pérez L, Shen G, Jour G, Meyn P, Carpenito J, Liu X, Ji K, Collazo D, Labarbiera A, Amoroso N, Brosnahan S, Mukherjee V, Kaufman D, Bakker J, Lubinsky A, Pradhan D, Sterman DH, Weiden M, Heguy A, Evans L, Uyeki TM, Clemente JC, de Wit E, Schmidt AM, Shopsin B, Desvignes L, Wang C, Li H, Zhang B, Forst CV, Koide S, Stapleford KA, Khanna KM, Ghedin E, Segal LN. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nat. Microbiol. 2021;6(10):1245–58. doi: 10.1038/s41564-021-00961-5
4. Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, Brophy JM, McDonald EG. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203–10. doi: 10.1016/j.cmi.2022.04.018
5. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial. Lancet. 2020;395(10236):1569–78. doi: 10.1016/S0140-6736(20)31022-9
6. Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis. 2022;75(1):e450–e458. doi: 10.1093/cid/ciab875
7. Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, Israelsen SB, Jensen J, Jensen TØ, Johansen IS, Johnsen S, Lindegaard B, Lundgren J, Meyer CN, Mohey R, Pedersen LM, Nielsen H, Nielsen SL, Obel N, Omland LH, Podlekareva D, Poulsen BK, Ravn P, Sandholdt H, Starling J, Storgaard M, Søborg C, Søgaard OS, Tranborg T, Wiese L, Christensen HR. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clin Infect Dis. 2021;73(11):2031–6. doi: 10.1093/cid/ciab536
8. State Register of Medicines (In Russ.) URL: https://grls.rosminzdrav.ru (Accessed April 26, 2024).
9. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141. doi: 10.1186/s12985-020-01412-z
10. Manabe T, Kambayashi D, Akatsu H, Kudo К. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):489. doi: 10.1186/s12879-021-06164-x
11. Teschke R, Danan G. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). Diagnostics (Basel). 2021;11(3):458. doi: 10.3390/diagnostics11030458
12. Zhuravleva MV, Kuznetsova EV, Kameneva TR, Kulikov AN, Laryushkina ED, Ivzhicz MA, Romashov OM, Rodionov BA, Galitskiy AA, Mitroxin SD, Mironov AYu. Register-based observational study of the efficacy and safety of favipiravir in patients with COVID-19 in medical organizations of the Moscow state healthcare system. Izvestiya GGTU. Medicina, Farmaciya. 2021;2:67–73 (In Russ.).
13. Kiselev YuYu, Matveev AV, Mirzaev KB, Sychev DA. Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;S4:115–9 (In Russ.) doi: 10.37489/2588-0519-2020-S4-115-119
14. Ruzhentsova TA, Chuchliaev PV, Khavkina DA, Garbuzov AA, Nikolskaya MV, Razzhivina VA, Filon OV. The necessity and safety of using favipiravir in the treatment of adult patients with mild COVID-19. Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy 2020;10(4):38–44. (In Russ.) doi: 10.18565/epidem.2021.10.4.38–44
15. Petrov VI, Ryazanova AYu, Privaltseva NS, Nekrasov DA. Experience of using remdesivir in patients with novel coronavirus infection. Safety and Risk of Pharmacotherapy. 2022;10(4):365–80 (In Russ.) doi: 10.30895/2312-7821-2022-10-4-365-380
Review
For citations:
Petrov V.I., Ryazanova A.Yu., Tokareva N.S. Efficacy and safety of favipiravir and remdesivir in COVID-19 patients: Clinical data. Pacific Medical Journal. 2024;(3):79-84. (In Russ.) https://doi.org/10.34215/1609-1175-2024-3-79-84
Views:
281
Email this article 